Autopsy report · NCT01153919

Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

“Approval of several new agents for the treatment of HCV infection would mitigate the future need for interferon HCV treatment”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 8 years before it stopped.
• 27 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Southern California

Sponsor type

University, hospital or other

Conditions

Hepatitis C Infection; Thrombocytopenia

Interventions

romiplostim; ribavirin; placebo; PEG-interferon alfa-2a; laboratory biomarker analysis

Participants

27

Sites

1

Countries

United States

Trials that died the same way

• Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)
  “The US FDA and the EU CHMP provided guidance indicating preference for intereferon-free regimens in pediatric studies of HCV infection.” (68% match in meaning)
• To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis
  “In view of recent approval of NS5A inhibitors for treatment of hepatitis C such as Declatasvir and Ledipasvir which have proven better efficacy in the HCV cure” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.